Rosen Law Firm reminds purchasers of Zoetis Inc. securities between January 14, 2025 and May 6, 2026 of the July 27, 2026 lead plaintiff deadline in a securities class action. The lawsuit alleges that during the class period, Zoetis made false or misleading statements about market share, veterinarian adoption, and sales growth for its companion animal products, while failing to disclose weakening prescription growth for Librela, market share losses for Simparica Trio, and competitive pressures on Apoquel and Cytopoint. Investors who purchased Zoetis securities during the class period may be entitled to compensation through a contingency fee arrangement. Rosen Law Firm, which has recovered billions for investors and was ranked number one by ISS Securities Class Action Services in 2017, encourages investors to select qualified counsel.
Zoetis IncSecurities class action lawsuit alleges false statements about market share and sales growth, with lead plaintiff deadline approaching.